美股異動 | BioNTech盤前漲1% 第四劑新冠疫苗對奧密克戎保護作用至少一個月
格隆匯4月19日丨BioNTech(BNTX.US)盤前漲1.4%,報161.8美元,總市值400億美元。以色列一項研究顯示,來自輝瑞和BioNTech第四劑新冠疫苗能為老年人提供了至少一個月的針對嚴重疾病、住院和死亡的顯著保護,此當時奧密克戎的變體占主導地位。與至少四個月前的第三次注射相比,第四次注射在給藥後7至30天內對感染的估計有效率為45%,對有症狀的疾病的有效率為55%,對住院的有效率為68%,對嚴重疾病的有效率為62%,對死亡的有效率為74%。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.